Tuesday

17th Oct 2017

UK big pharma loses EU court battle over cheaper drugs

UK pharmaceutical firms have been defeated in their attempt to put an end to British government incentives to doctors to supply patients with cheaper but equivalent medicines.

The European Court of Justice rejected a complaint by the Association of the British Pharmaceutical Industry (ABPI) that such National Health Service (NHS) schemes were not an illegal inducement under EU law.

Thank you for reading EUobserver!

Subscribe now for a 30 day free trial.

  1. €150 per year
  2. or €15 per month
  3. Cancel anytime

EUobserver is an independent, not-for-profit news organization that publishes daily news reports, analysis, and investigations from Brussels and the EU member states. We are an indispensable news source for anyone who wants to know what is going on in the EU.

We are mainly funded by advertising and subscription revenues. As advertising revenues are falling fast, we depend on subscription revenues to support our journalism.

For group, corporate or student subscriptions, please contact us. See also our full Terms of Use.

If you already have an account click here to login.

  • UK health authorities are not seeking commercial advantage by the incentive scheme (Photo: Flickr)

In order to reduce public expenditure, the public health authorities in England and Wales introduced schemes providing doctors with financial incentives to prescribe cheap generic drugs rather than their more expensive patented counterparts.

A 2001 European directive relating to medicinal products prohibits "pecuniary advantages or benefits in kind" from being offered to doctors or pharmacists.

The bill aimed to prevent drug firms from offering incentives such as holidays, golf club memberships or other bonuses for prescribing their product, but in an attempted reversal of the legislation's original intention, the companies argued that rewards to medical practices acted in the same way.

But the court found that the directive was concerned primarily with the promotional activities carried out by the pharmaceutical industry and sought to prevent promotional practices that could push doctors to act more in line with their wallet than a patient's interest.

"By contrast, that prohibition does not apply to national public health authorities which ... do not pursue any profit-making or commercial aim," the court said in its ruling.

"Therefore, the financial incentive scheme examined, which forms part of such a policy, cannot be regarded as seeking the promotion of commercial promotion of medicinal products."

"No danger to public health can be established," the court concluded.

News in Brief

  1. EU to keep 'Dieselgate' letter secret
  2. No deal yet on Mediterranean alliance for EU agencies
  3. EU Commission condemns Maltese journalist's murder
  4. Poland denies wrongdoing over forest logging
  5. Risk to asylum kids in EU increasing, says charity
  6. Schroeder warns of Turkey and Russia drifting towards China
  7. EU parliament wants equal pay for posted workers
  8. Catalan independence leaders taken into custody

Stakeholders' Highlights

  1. EU2017EENorth Korea Leaves Europe No Choice, Says Estonian Foreign Minister Sven Mikser
  2. Mission of China to the EUZhang Ming Appointed New Ambassador of the Mission of China to the EU
  3. International Partnership for Human RightsEU Should Seek Concrete Commitments From Azerbaijan at Human Rights Dialogue
  4. European Jewish CongressEJC Calls for New Austrian Government to Exclude Extremist Freedom Party
  5. CES - Silicones EuropeIn Healthcare, Silicones Are the Frontrunner. And That's a Good Thing!
  6. EU2017EEEuropean Space Week 2017 in Tallinn from November 3-9. Register Now!
  7. European Entrepreneurs CEA-PMEMobiliseSME Exchange Programme Open Doors for 400 Companies Across Europe
  8. CECEE-Privacy Regulation – Hands off M2M Communication!
  9. ILGA-EuropeHealth4LGBTI: Reducing Health Inequalities Experienced by LGBTI People
  10. EU2017EEEHealth: A Tool for More Equal Health
  11. Mission of China to the EUChina-EU Tourism a Key Driver for Job Creation and Enhanced Competitiveness
  12. CECENon-Harmonised Homologation of Mobile Machinery Costs € 90 Million per Year

Latest News

  1. Nepal troops arrive in Libya to guard UN refugee agency
  2. Is Banking Authority HQ the Brexit 'booby prize'?
  3. EU-Russia trade bouncing back - despite sanctions
  4. No sign of Brexit speed-up after May-Juncker dinner
  5. EU defence strategy 'outsourced' to arms industry
  6. EU privacy rules tilt to industry, NGO says
  7. Malta in shock after car bomb kills crusading journalist
  8. Spanish and Catalan leaders continue stand-off